Skip to content
TriangleGet started
← Full study record

NCT00866047 · OUTCOME

Progression-free Survival by Kaplan-Meier Analysis

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma · Source last updated 2017-03-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
up to approximately 3 years

What was measured

Time from start of study treatment to disease progression per independent review group or death due to any cause.

Analysis population: Intention to treat

Groups in this outcome

Brentuximab Vedotin

Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Brentuximab Vedotin58

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Brentuximab Vedotin14.6Not reported6.920.6Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        6.9
        upper Limit
        20.6
        value
        14.6
denoms
  1. counts
    1. group Id
      OG000
      value
      58
    units
    Participants
description
Time from start of study treatment to disease progression per independent review group or death due to any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
    id
    OG000
    title
    Brentuximab Vedotin
param Type
MEDIAN
population Description
Intention to treat
reporting Status
POSTED
time Frame
up to approximately 3 years
title
Progression-free Survival by Kaplan-Meier Analysis
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice